Vincerx Pharma, Inc. (VINC)
After hours:
| Previous close | 0.8967 |
| Open | 0.7900 |
| Bid | 0.6948 x 100 |
| Ask | 0.7616 x 100 |
| Day's range | 0.6607 - 0.8460 |
| 52-week range | 0.6100 - 9.3720 |
| Volume | |
| Avg. volume | 1,176,947 |
| Market cap | 15.632M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8900 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
GlobeNewswireVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock, and (ii) to certain investors, pre-funded warrants to purchase up to an aggregate of 16,000,000 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 16,000,000
- GlobeNewswire
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and common stock warrants in the proposed offe
ZacksVincerx (VINC) Tumbles on Results From Cancer Therapy Study
Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.
